CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
This is the first update to the original CTS communication distributed on July 6th. As previously co...
The new online Learning Center with new content can still be found under the “Training” folder on ...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization